Category: 3. Business

Award-winning actor named Global Brand Ambassador in multi-year partnership, a first for the visionary EV maker redefining what it means to ‘Compromise Nothing’

NEWARK, Calif. – July 29, 2025 – Lucid Group, Inc. (NASDAQ: LCID), maker of the world’s most advanced electric vehicles, today announced it has signed a multi-year partnership with award-winning actor and culture icon, Timothée Chalamet, as its first-ever Global Brand Ambassador. 

Chalamet was first spotted driving a Lucid Air in 2023, and since then, a relationship has been built rooted in the belief that performance, design, and passion are key to creating exceptional experiences. Later this year, Chalamet will headline Lucid’s new marketing campaign for the EV maker’s groundbreaking SUV, the Lucid Gravity. The partnership is a key milestone in Lucid’s strategy to broaden cultural relevance of the brand through accelerated marketing efforts.

Since launching in 2016, Lucid has quickly become one of the world’s most critically acclaimed new automotive companies, and its first product – the award-winning, all-electric Lucid Air – represents a masterful blend of performance, range, comfort, and technology. The company’s latest product, the Lucid Gravity SUV, delivers the versatility of a sophisticated full-size, three-row SUV with the performance of a luxury sports car.

“We’re excited to welcome Timothée as our first Global Brand Ambassador,” said Akerho “AK” Oghoghomeh, Senior Vice President of Marketing at Lucid Motors. “He brings together the same fearless creativity and uncompromising vision that defines our brand, embodying what it means to compromise nothing, both on and off screen. Together, we’ll show what’s possible when innovation and cultural relevance come together to move the world forward.”

Chalamet has been nominated for two Academy Awards and recently won his first Screen Actors Guild Award for his portrayal of Bob Dylan in 2024’s A Complete Unknown, directed by James Mangold. Later this year he will star in Marty Supreme, directed by Josh Safdie and next year he will be starring in Dune: Part Three, directed by Denis Villeneuve. 

Lucid’s new campaign starring Chalamet will premiere early this fall, with additional details forthcoming.

About Lucid Group 
Lucid (NASDAQ: LCID) is a Silicon Valley-based technology company focused on creating the most advanced EVs in the world. The award-winning Lucid Air and new Lucid Gravity deliver best-in-class performance, sophisticated design, expansive interior space and unrivaled energy efficiency. Lucid assembles both vehicles in its state-of-the-art, vertically integrated factory in Arizona. Through its industry-leading technology and innovations, Lucid is advancing the state-of-the-art of EV technology for the benefit of all.  

Investor Relations Contact
investor@lucidmotors.com

Media Contact 
media@lucidmotors.com 

Trademarks 
This communication contains trademarks, service marks, trade names and copyrights of Lucid Group, Inc. and its subsidiaries and other companies, which are the property of their respective owners.

Forward-Looking Statements
This communication includes “forward-looking statements” within the meaning of the “safe harbor” provisions of the United States Private Securities Litigation Reform Act of 1995. Forward-looking statements may be identified by the use of words such as “estimate,” “plan,” “project,” “forecast,” “intend,” “will,” “shall,” “expect,” “anticipate,” “believe,” “seek,” “target,” “continue,” “could,” “may,” “might,” “possible,” “potential,” “predict” or other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. These forward-looking statements include, but are not limited to, statements regarding plans and expectations with respect to Lucid’s partnership with Mr. Chalamet, anticipated benefits as well as future collaborations. These statements are based on various assumptions, whether or not identified in this communication, and on the current expectations of Lucid’s management. These forward-looking statements are not intended to serve as and must not be relied on by any investor as a guarantee, an assurance, or a definitive statement of fact or probability. Actual events and circumstances are difficult or impossible to predict and may differ from these forward-looking statements. Many actual events and circumstances are beyond the control of Lucid. These forward-looking statements are subject to a number of risks and uncertainties, including those factors discussed under the heading “Risk Factors” in Part II, Item 1A of Lucid’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as well as other documents Lucid has filed or will file with the Securities and Exchange Commission. If any of these risks materialize or Lucid’s assumptions prove incorrect, actual results could differ materially from the results implied by these forward-looking statements. There may be additional risks that Lucid currently does not know or that Lucid currently believes are immaterial that could also cause actual results to differ from those contained in the forward-looking statements. In addition, forward-looking statements reflect Lucid’s expectations, plans or forecasts of future events and views as of the date of this communication. Lucid anticipates that subsequent events and developments will cause Lucid’s assessments to change. However, while Lucid may elect to update these forward-looking statements at some point in the future, Lucid specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing Lucid’s assessments as of any date subsequent to the date of this communication. Accordingly, undue reliance should not be placed upon the forward-looking statements.

New Models Clarify Roles

The authors propose a careful, measured approach to role separation—guided by rigorous clinical validation and real-world evidence—as the most pragmatic path forward. Their framework includes three models: 

• AI-First Sequential Model—Where effective, AI processes the initial segment of the workflow (e.g., preparing clinical context from electronic health records), followed by the radiologist providing expert interpretation.  
• Doctor-First Sequential Model—The radiologist initiates the diagnostic process while AI performs complementary tasks such as report generation and follow-up recommendations to enhance the workflow. 
• Case Allocation Model—Cases are triaged based on complexity and clarity, with some managed entirely by AI, others by a radiologist, and the rest through a combination of both. 

“Radiologists are stuck in the worst of both worlds—afraid to trust AI fully, but too reliant to ignore it,” Dr. Rajpurkar said. “Clear role separation breaks this cycle.” 

The authors envision institutions implementing their framework through repeated interactions rather than strict, sequential processes. 

“We’re providing a framework, but the real innovation will come from frontline radiologists adapting it to their specific needs,” Dr. Rajpurkar said. “Institutions will likely discover hybrid approaches we haven’t even imagined yet.”  

For example, a trauma center might use the AI-First model to review chest X-rays overnight, then switch to a Doctor-First model when teaching residents. Under the Case Allocation model, an AI screening system may identify and ‘clear’ normal results, escalating only abnormal cases to the radiologist for review.  

“The breakthrough moment comes when practices stop asking ‘Which model?’ and start asking ‘Which model when?’” he said. “That’s where the magic happens—adaptive workflows that respond to real-time clinical needs, not rigid theoretical constructs.” 

Implementing their vision will require carefully designed pilot programs to test the models in real clinical environments, measuring accuracy, workflow efficiency, radiologist satisfaction and downstream outcomes. 

“Results must be shared openly; the field desperately needs honest case studies,” Dr. Rajpurkar said. “Our framework gives radiologists not another promise of AI magic, but a concrete, practical roadmap for integration that acknowledges both the current limitations and the inevitable evolution of AI.” 

The researchers also suggest establishing a clinical certification pathway for AI systems, something no single agency is equipped to handle alone.  

“The Food & Drug Administration needs to maintain safety oversight, but clinical certification requires understanding real-world workflow integration, which goes beyond traditional regulatory scope,” Dr. Rajpurkar said. “We need new models, perhaps independent certification bodies with input from multiple stakeholders and consortia that bring together clinical expertise, technical knowledge and implementation experience.” 

The researchers are awaiting the emergence of general medical AI systems capable of handling routine tasks, preparing cases, and drafting reports, all while learning the patterns of the practice. 

“We’re not there yet,” Dr. Rajpurkar said. “But when these systems can competently manage the breadth of tasks a senior medical resident handles, the entire conversation changes. That’s the inflection point we’re watching for.” 

For More Information

Access the Radiology editorial, “Beyond Assistance: The Case for Role Separation in AI-Human Radiology Workflows.”  

Read previous RSNA News stories about AI in medical imaging:

A supplemental new drug application seeking the approval of the fixed-duration, all-oral combination of venetoclax (Venclexta) plus acalabrutinib (Calquence) for previously untreated patients with chronic lymphocytic leukemia (CLL) has been submitted to the FDA.¹

The application is supported by data from the phase 3 AMPLIFY trial (NCT03836261), which showed a statistically significant improvement in progression-free survival (PFS) with the combination vs standard chemoimmunotherapy in this patient population.¹

Findings published in the New England Journal of Medicine showed that the median PFS was not reached with either acalabrutinib plus venetoclax or acalabrutinib plus venetoclax and obinutuzumab (Gazyva) vs 47.6 months with chemoimmunotherapy.² This translated to a 35% reduction in the risk of disease progression or death with acalabrutinib plus venetoclax (HR, 0.65; 95% CI, 0.49-0.87; P = .0004) and 58% reduction in the risk of disease progression or death with acalabrutinib plus venetoclax and obinutuzumab (HR 0.42; 95% CI, 0.30-0.59; P < .0001).^1,2

“This FDA submission marks a milestone for CLL treatment with the potential approval for the first oral combination regimen of venetoclax and acalabrutinib for previously untreated patients with chronic blood cancer,” Svetlana Kobina, vice president of global medical affairs and oncology at AbbVie stated in a news release.¹ “This new fixed-treatment duration approach could allow patients the opportunity for time off treatment, if approved, and be potentially practice-changing in frontline CLL care.”

Notably, data from AMPLIFY also supported the European approval of fixed-duration acalabrutinib plus venetoclax with or without obinutuzumab for patients with treatment-naive CLL in June 2025.²

AMPLIFY Trial Overview

AMPLIFY was a global, multi-center, open-label trial evaluating venetoclax plus acalabrutinib alone or in combination with obinutuzumab vs chemoimmunotherapy in patients with previously untreated CLL without 17p deletion or TP53 mutation.¹ Upon enrollment, patients were randomly assigned 1:1:1 to receive either acalabrutinib-based regimen for 14, 28-day cycles, or standard-of-care chemoimmunotherapy for 6 cycles.

The study’s primary end point was PFS per independent review committee assessment in the acalabrutinib plus venetoclax arm. Secondary end points comprised PFS in the acalabrutinib plus venetoclax and obinutuzumab arm, overall survival (OS), and undetectable measurable residual disease.

Additional Efficacy and Safety Data

Additional efficacy data from AMPLIFY showed that, at a median follow-up of 40.8 months, the estimated 36-month PFS rate was 76.5% with acalabrutinib plus venetoclax, 83.1% with acalabrutinib plus venetoclax and obinutuzumab, and 66.5% with chemoimmunotherapy (HR, 0.65; 95% CI, 0.49-0.87; P = 0.004).³ The estimated 36-month OS rates were 94.1%, 87.7%, and 85.9% for these respective regimens.

The safety and tolerability profile of the combination regimen was also consistent with the known profiles of each individual agent, and no new safety signals were identified.¹ The most common any-grade adverse effects (AE) with the acalabrutinib plus venetoclax regimen were neutropenia, hemorrhage, and COVID-19.

Regarding adverse effects (AE) of clinical interest, the most frequently observed grade 3 or higher event was neutropenia; this was reported in 32.3%, 46.1%, and 43.2% in the acalabrutinib plus venetoclax, acalabrutinib plus venetoclax and obinutuzumab, and chemoimmunotherapy groups, respectively.³ The incidence of any-grade tumor lysis syndrome was low, with an incidence of 0.3% in patients treated with acalabrutinib plus venetoclax compared with 3.1% in patients treated with chemoimmunotherapy. ¹

References

1. AbbVie submits for U.S. FDA approval of combination treatment of Venclexta (venetoclax) and acalabrutinib for previously untreated patients with chronic lymphocytic leukemia (CLL).News release. AbbVie. July 29, 2025. Accessed July 29, 2025. https://news.abbvie.com/2025-07-29-AbbVie-Submits-for-U-S-FDA-Approval-of-Combination-Treatment-of-VENCLEXTA-R-venetoclax-and-Acalabrutinib-for-Previously-Untreated-Patients-with-Chronic-Lymphocytic-Leukemia-CLL
2. Fixed-duration Calquence-based regimens approved in EU for patients with chronic lymphocytic leukaemia in the 1st-line setting. News release. AstraZeneca. June 6, 2025. Accessed July 29, 2025. https://www.astrazeneca.com/media-centre/press-releases/2025/fixed-duration-calquence-approved-in-eu-for-1l-cll.html
3. Brown JR, Seymour JF, Jurczak W, et al. Fixed-duration acalabrutinib combinations in untreated chronic lymphocytic leukemia. N Engl J Med. 2025;392(8):748-762. doi:10.1056/NEJMoa2409804

29 July 2025 – Tullow Oil plc (Tullow) is pleased to announce that it has successfully completed the sale of its assets in Gabon to the Gabon Oil Company (GOC) following satisfaction of all conditions precedent under the Sale and Purchase Agreement (SPA), with the full proceeds now received by Tullow. The transaction represents the sale of 100% of the shares in Tullow’s subsidiary Tullow Oil Gabon S.A., which holds all of Tullow’s non-operated working interests in Gabon, for a total cash consideration of US$307 million net of tax and customary adjustments.

The sale of its Gabon assets marks Tullow’s exit from its licences in Gabon after 21 years. The transaction proceeds will be used to strengthen Tullow’s balance sheet by materially reducing Tullow’s net debt.

Richard Miller, Chief Financial Officer and Interim Chief Executive Officer of Tullow, commented:

“Today’s news represents another key milestone that accelerates the deleveraging of Tullow. I am pleased with the momentum we have at Tullow, and I look forward to this continuing in the weeks and months ahead. Our immediate focus is on successfully completing the Kenya transaction in 2025 and the current Ghana drilling campaign with the first well, a Jubilee producer, now onstream.”

Further information

On 21 May 2025, Tullow entered into an extension of its Revolving Credit Facility (RCF) to 31 October 2025 at reduced commitments of US$150 million. As noted in the Group’s AGM Statement on 22 May 2025, following completion of the sale of its Gabon assets, Tullow will apply part of the transaction proceeds to repay in full and simultaneously cancel the RCF.

On 21 July 2025, Tullow Overseas Holdings BV signed an SPA with Auron Energy E&P Ltd, an affiliate of Gulf Energy Ltd to sell Tullow Kenya BV, which holds Tullow’s entire working interests in Kenya, for a minimum cash consideration of US$120 million, subject to customary adjustments (Kenya Transaction). Further details of the Kenya Transaction are set out in the significant transaction announcement, released by Tullow on the same date. In addition, Tullow has received an extension of the field development plan review period for blocks 10BB and 13T in the South Lokichar Basin to 31 December 2025.

Other than the disclosures above in respect to the RCF, the Kenya Transaction and the extension of the field development plan review period, Tullow confirms that there has been no material change affecting any matter contained in Tullow’s announcement of the Transaction on 13 May 2025 under UK Listing Rules 7.3.1R or 7.3.2R “material” for these purposes having the meaning given to it in UK Listing Rule 7.3.14R.

Defined terms used in this announcement have the same meaning given to them in Tullow’s announcement dated 13 May 2025, unless otherwise defined herein.

WASHINGTON — Employers posted 7.4 million job vacancies last month, a sign that the American job market continues to cool.

The Labor Department reported Tuesday that job openings in June were down from 7.7 million in May.

Layoffs were little changed. But the number of people quitting their jobs — a sign of confidence in their prospects elsewhere — dropped last month.

The U.S. job market has lost momentum this year, partly because of the lingering effects of 11 interest rate hikes by the inflation fighters at the Federal Reserve in 2022 and 2023 and partly because President Donald Trump’s trade wars have created uncertainty that is paralyzing managers making hiring decisions.

On Friday, the Labor Department will put out unemployment and hiring numbers for July. They are expected to show that the unemployment rate ticked up to a still-low 4.2% in July from 4.1% in June. Businesses, government agencies and nonprofits are expected to have added 115,000 jobs in July, down from 147,000 in June, according to a survey of economists by the data firm FactSet.

The seemingly decent June hiring numbers were weaker than they appeared. Private payrolls rose just 74,000 in June, fewest since last October when hurricanes disrupted job sites. And state and local governments added nearly 64,000 education jobs in June – a total that economists suspect was inflated by seasonal quirks around the end of the school year.

So far this year, the economy has been generating 130,000 jobs a month, down from 168,000 last year and an average 400,000 a month from 2021 through 2023 during the recovery from COVID-19 lockdowns.

Treatment with the novel LYN/BTK dual inhibitor DZD8586 yielded antitumor activity with a manageable safety profile in heavily pretreated patients with relapsed/refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL), according to pooled data from the phase 2 TAI-SHAN8 (NCT06539182) and phase 1 TAI-SHAN-5 (NCT05824585) trials.

Findings reported at the 2025 EHA Congress demonstrated that patients treated with DZD8586 at 50 mg once per day (n = 19) achieved an overall response rate (ORR) of 84.2%. Those treated at a dose of 75 mg once per day (n = 15) experienced an ORR of 68.8%. Between these 2 dose levels, 94.1% of patients experienced tumor shrinkage.

The 50-mg dose was selected as the recommended phase 3 dose. Regarding the safety of this dose level, no instances of major cardiac adverse effects (AEs), such as atrial fibrillation or QT prolongation, were reported. No patients experienced drug-related bleeding, and no treatment-emergent AEs (TEAEs) related to treatment led to death.

“Tumor response [was] observed irrespective of prior covalent/noncovalent BTK inhibitor, BTK degrader, or BCL-2 inhibitor treatment, and in patients with classic BTK resistance mutations [C481X] as well as other BTK mutations, including kinase-dead mutations,” lead study author Jianyong Li, MD, PhD, and colleagues wrote in a poster presentation of the data. Li is a professor and director of the Department of Hematology at First Affiliated Hospital of Nanjing Medical University at Jiangsu Province Hospital in China.

DZD8586 and Study Backgrounds

Through the dual inhibition of BTK and LYN, DZD8586 is intended to block BTK-dependent and -independent B-cell receptor signaling pathways and inhibit resistance mutations against BTK degraders. Additionally, the agent has displayed high selectivity against other members of the TEC gene family beyond BTK.

The phase 1 and 2 trials enrolled patients with previously treated CLL/SLL requiring additional therapy per 2018 International Working Group guidelines. At least 1 prior line of systemic therapy was required. Notably, prior treatment with noncovalent BTK inhibitors, BTK degraders, and BCL-2 inhibitors was allowed.

In the phase 2 TAI-SHAN8 trial, patients received DZD8586 at once-daily doses of 25 mg, 50 mg, or 75 mg. In the phase 2 TAI-SHAN5 study, the agent was given at once-daily doses ranging from 50 mg to 100 mg. TAI-SHAN5 also included patients with other relapsed/refractory B-cell malignancies.

The studies’ primary end point was ORR per investigator assessment. Secondary end points comprised progression-free survival (PFS), duration of response (DOR), safety, and pharmacokinetics.

In the pooled safety population (n = 51), the median age was 63 years (range, 34-84). The majority of patients were male (66.7%), Asian (92.2%), and had an ECOG performance status of 1 or higher (60.8%). Forty percent of patients harbored 17p deletions and/or TP53 mutations. BTK C481X mutations and other BTK mutations were reported in 35.7% and 19.0% of patients, respectively.

Patients received a median of 2 prior lines of therapy (range, 1-8). Prior treatments included any BTK inhibitor (74.5%), a covalent BTK inhibitor (68.6%), a noncovalent BTK inhibitor (11.8%), a BTK degrader (9.8%), chemoimmunotherapy (56.9%), and a BCL-2 inhibitor (35.3%).

Additional Data for the 50-mg Dose

Findings also showed that among patients treated at the 50-mg dose level, the ORR was 82.4% in patients previously treated with a BTK inhibitor, 83.3% in those previously administered a BCL-2 inhibitor, and 50% in patients who received a prior BTK degrader.

In the 50-mg cohort, the median duration of treatment exceeded 7 months, and 78.9% of patients remained on treatment. PFS data were immature, and the estimated 9-month DOR rate was 83.3%.

In the 50-mg safety population (n = 30), treatment-related TEAEs occurred at rates of 76.7% (any grade) and 43.3% (grade ≥3). The most common comprised thrombocytopenia (50.0%; 3.3%), neutropenia (33.8%; 26.7%), increased aspartate aminotransferase levels (10.0%; 3.3%), increased alanine aminotransferase levels (3.3%; 3.3%), pneumonia (13.3%; 6.7%), anemia (13.3%; 0%), increased blood creatinine levels (10.0%; 0%), nausea (10.0%; 0%), and decreased white blood cell count (6.7%; 0%).

Reference

Li J, Zhou KS, Zhu H, et al. Phase 1/2 studies of DZD8586 in CLL/SLL patients after covalent or non-covalent BTK inhibitors and BTK degraders. Presented at: 2025 EHA Congress; June 12-15, 2025; Milan, Italy. Abstract PF570.

Bezons, France – July 29, 2025

Atos, a global AI-powered technology partner shaping secure, end-to-end digital journeys, has been named as Leader in Industry transformation services in Europe by Information Services Group (ISG), the leading global research and advisory firm.

Industry Transformation Services

The report assesses providers specializing in operational and business consulting services by leveraging technology that helps manufacturing companies enhance process efficiency and productivity, accelerate innovation and achieve sustainability goals.

The report highlights Atos as a leader in digital transformation services across Europe, especially in the manufacturing industry. It provides advanced AI solutions, smart factory technologies and digital ecosystems to optimize production.

Harish B, Manager and Principal Analyst, ISG mentions that “Atos is a prominent player in the manufacturing industry transformation services space in Europe, leveraging its expertise in digital technologies to enhance manufacturing processes.”

The assessment acclaimed Atos’ strengths in Collaboration with major industry players. It collaborates with leading automotive manufacturers and other significant players in the manufacturing sector. For example, the company is involved in projects such as the European e-BEAT initiative, which aims to optimize electric vehicle manufacturing through intelligent decision-making tools.

The report accolades Atos’ role to Support for gigafactories. It plays a vital role in supporting the ramp-up of gigafactories for electric vehicle batteries across Europe. It manages IT infrastructure for Automotive cells company’s facilities in France, Germany and Italy, ensuring robust operational capabilities as the demand for electric vehicles grows.

ISG also acknowledges Atos’ R&D initiatives. With a strong R&D focus, it is involved in numerous projects aimed at advancing manufacturing technologies. Its dedicated research teams work on innovations that enhance data intelligence and operational performance within the manufacturing sector. It tailors its services to various segments within the manufacturing industry, including automotive, consumer packaged goods, aerospace and chemicals.

Download the PDF document

***

About Atos Group

Atos Group is a global leader in digital transformation with c. 72,000 employees and annual revenue of c. € 10 billion, operating in 68 countries under two brands — Atos for services and Eviden for products. European number one in cybersecurity, cloud and high-performance computing, Atos Group is committed to a secure and decarbonized future and provides tailored AI-powered, end-to-end solutions for all industries. Atos is a SE (Societas Europaea) and listed on Euronext Paris.

The purpose of Atos is to help design the future of the information space. Its expertise and services support the development of knowledge, education and research in a multicultural approach and contribute to the development of scientific and technological excellence. Across the world, the Group enables its customers and employees, and members of societies at large to live, work and develop sustainably, in a safe and secure information space.

Press contact

Laurent Massicot | laurent.massicot@atos.net